Literature DB >> 2375629

Amyotrophic lateral sclerosis: amino acid levels in plasma and cerebrospinal fluid.

T L Perry1, C Krieger, S Hansen, A Eisen.   

Abstract

Concentrations of glutamic acid have been reported to be elevated in fasting plasma and cerebrospinal fluid (CSF) of patients with amyotrophic lateral sclerosis (ALS); glycine concentrations have also been reported to be increased in the CSF of such patients. Autopsy studies have shown glutamate contents to be significantly decreased in brain and spinal cord in ALS. These observations suggested that a systemic abnormality of glutamate metabolism might underlie the pathogenesis of ALS. We report here the findings of our studies of amino acid concentrations in patients with the sporadic form of ALS. Glutamate concentrations were normal in the fasting plasma of a great majority of the patients with ALS. Concentrations of glutamate, aspartate, and glycine were normal in the CSF of all 17 patients examined. beta-N-Methylamino-L-alanine, a plant neurotoxin possibly responsible for causing the Guamanian form of ALS, was not detectable in the plasma or CSF of any of our patients. Our findings do not lend support to the hypothesis that the sporadic form of ALS results from overexcitation of motor neurons by excitatory amino acids.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2375629     DOI: 10.1002/ana.410280105

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  22 in total

1.  Fragmentation of the Golgi apparatus of motor neurons in amyotrophic lateral sclerosis.

Authors:  N K Gonatas; A Stieber; Z Mourelatos; Y Chen; J O Gonatas; S H Appel; A P Hays; W F Hickey; J J Hauw
Journal:  Am J Pathol       Date:  1992-03       Impact factor: 4.307

2.  A gain-of-function of an amyotrophic lateral sclerosis-associated Cu,Zn-superoxide dismutase mutant: An enhancement of free radical formation due to a decrease in Km for hydrogen peroxide.

Authors:  M B Yim; J H Kang; H S Yim; H S Kwak; P B Chock; E R Stadtman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

3.  Effects of branched-chain amino acids on plasma amino acids in amyotrophic lateral sclerosis.

Authors:  O Gredal; S E Møller
Journal:  Amino Acids       Date:  1996-03       Impact factor: 3.520

Review 4.  Motor neuron disease: etiology, pathogenesis and treatment--a review.

Authors:  D J Donohoe; B Brady
Journal:  Ir J Med Sci       Date:  1996 Jul-Sep       Impact factor: 1.568

5.  Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease.

Authors:  M Nagai; M Aoki; I Miyoshi; M Kato; P Pasinelli; N Kasai; R H Brown; Y Itoyama
Journal:  J Neurosci       Date:  2001-12-01       Impact factor: 6.167

Review 6.  Glutamate, excitotoxicity and amyotrophic lateral sclerosis.

Authors:  P J Shaw; P G Ince
Journal:  J Neurol       Date:  1997-05       Impact factor: 4.849

Review 7.  Positron emission tomography in amyotrophic lateral sclerosis: Towards targeting of molecular pathological hallmarks.

Authors:  Stefanie M A Willekens; Donatienne Van Weehaeghe; Philip Van Damme; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-08       Impact factor: 9.236

Review 8.  Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease.

Authors:  Christi Kolarcik; Robert Bowser
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

9.  Changes in CSF amino acid concentrations during the evolution of amyotrophic lateral sclerosis.

Authors:  O Blin; D Samuel; A Nieoullon; G Serratice
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-01       Impact factor: 10.154

Review 10.  MicroRNAs as potential circulating biomarkers for amyotrophic lateral sclerosis.

Authors:  Frank Cloutier; Alier Marrero; Colleen O'Connell; Pier Morin
Journal:  J Mol Neurosci       Date:  2014-11-30       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.